From Globe Newswire:

Cytokinetics, Incorporated will be presenting their findings on the effects of Aficamten on patients with obstructive hypertrophic cardiomyopathy at CMR 2024. The upcoming conference takes place online and in London, UK from January 25-27, 2024. The session is titled Rapid Fire – Large Clinical Trials and Registries, and the company has several Phase 3 clinical trials ongoing for its drug candidates.

As a specialty cardiovascular biopharmaceutical company, Cytokinetics is developing first-in-class muscle activators and next-in-class muscle inhibitors to treat diseases affecting cardiac muscle performance. Aficamten is undergoing regulatory interactions following positive trial results, and it is also being evaluated in two ongoing Phase 3 clinical trials. The company is also developing other drug candidates for the potential treatment of various types of heart failure.

Cytokinetics wants to update investors and shareholders about its research and development activities of its product candidates. It wants to keep a transparent and informative communication policy with respect to its trials and developments of its new cardiological and cardiovascular drugs. Any news and progress updates of the company will be posted on its official website and social media channels.



Read more: Cytokinetics Announces New Data From FOREST-HCM to be